Nonreciprocity in CHIKV and MAYV Vaccine-Elicited Protection
Authors:
- Whitney C. WeberWWWhitney C. Weber
- Takeshi F. AndohTATakeshi F. Andoh
- Craig N. KreklywichCKCraig N. Kreklywich
- Zachary J. StreblowZSZachary J. Streblow
- Michael DentonMDMichael Denton
- Magdalene M. StreblowMSMagdalene M. Streblow
- John M. PowersJPJohn M. Powers
- Gauthami SulgeyGSGauthami Sulgey
- Samuel MedicaSMSamuel Medica
- Igor DmitrievIDIgor Dmitriev
- David T. CurielDCDavid T. Curiel
- Nicole N. HaeseNHNicole N. Haese
Open Access
Abstract
Chikungunya virus (CHIKV) is a pathogenic arthritogenic alphavirus responsible for large-scale human epidemics for which a vaccine was recently approved for use. Mayaro virus (MAYV) is a related emerging alphavirus with epidemic potential with circulation overlap potential with CHIKV. We previously reported the ability of a non-replicating human adenovirus (AdV)-vectored vaccine expressing the MAYV structural polyprotein to protect against disease in mice following challenge with MAYV, CHIKV and UNAV. Herein, we evaluated mouse immunity and protective efficacy for an AdV-CHIKV full structural polyprotein vaccine in combination with heterologous AdV-MAYV prime/boost regimens versus vaccine coadministration. Heterologous prime/boost regimens skewed immunity toward the prime vaccine antigen but allowed for a boost of cross-neutralizing antibodies, while vaccine co-administration elicited robust, balanced responses capable of boosting. All immunization strategies protected against disease from homologous virus infection, but reciprocal protective immunity differences were revealed upon challenge with heterologous viruses. In vivo passive transfer experiments reproduced the inequity in reciprocal cross-protection after heterologous MAYV challenge. We detected in vitro antibody-dependent enhancement of MAYV replication, suggesting a potential mechanism for the lack of cross-protection. Our findings provide important insights into rational alphavirus vaccine design that may have important implications for the evolving alphavirus vaccine landscape.Keywords
Funding Information
- U.S. National Institute of Health (R41 AI38964-01)
This publication has 69 references indexed in Scilit:
- Clinical and laboratory diagnosis of Mayaro virus (MAYV): Current status and opportunities for further developmentReviews in Medical Virology, 2024
- Drugs targeting structural and nonstructural proteins of the chikungunya virus: A reviewInternational Journal of Biological Macromolecules, 2024
- An overview of anti-Chikungunya antibody response in natural infection and vaccine-mediated immunity, including anti-CHIKV vaccine candidates and monoclonal antibodies targeting diverse epitopes on the viral envelopeThe Microbe, 2023
- The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodiesCell Reports, 2021
- Human mAbs Broadly Protect against Arthritogenic Alphaviruses by Recognizing Conserved Elements of the Mxra8 Receptor-Binding SiteCell Host & Microbe, 2020
- Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohortInternational Journal of Infectious Diseases, 2020
- Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability OutcomesJAMA, 2020
- Small Molecule Inhibitors Targeting Chikungunya Virus2020
- Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and EgressCell, 2015
- A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritisVaccine, 2011